CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 5931-5939

  Casares, Noelia ^a   Arribillaga, Laura ^a   Sarobe, Pablo ^a   Dotor, Javier ^a   De Cerio, Ascensión Lopez Diaz ^a   Melero, Ignacio ^a   Prieto, Jesús ^a   Borrás Cuesta, Francisco ^a   Lasarte, Juan J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PEPTIDE AH1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CELL ACTIVITY; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HELPER CELL; IMMUNE RESPONSE; INHIBITION KINETICS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

EID: 0344153890     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.5931     Document Type: Article

References (50)

1. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389.
2. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162:5317.
3. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969.
4. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
5. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.
6. + T cells. J. Autoimmun. 16:115.
7. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 62:5267.
8. + T cells. J. Exp. Med. 183:2669.
9. Melero, I., N. Bach, and L. Chen. 1997. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci. 60:2035.
10. Melief, C. J., R. E. Toes, J. P. Medema, S. H. van der Burg, F. Ossendorp, and R. Offringa. 2000. Strategies for immunotherapy of cancer. Adv. Immunol. 75:235.
11. Sakaguchi, S., M. Toda, M. Asano, M. Itoh, S. S. Morse, and N. Sakaguchi. 1996. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9:211.
12. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160:1212.
13. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61:8643.
14. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823.
15. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59:3128.
16. + T cell responses. J. Exp. Med. 196:1585.
17. + T cells. Proc. Natl. Acad. Sci. USA 99:8832.
18. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730.
19. Casares, N., J. J. Lasarte, A. L. de Cerio, P. Sarobe, M. Ruiz, I. Melero, J. Prieto, and F. Borras-Cuesta. 2001. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 31:1780.
20. Merrifield, R. B. 1963. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:2149.
21. Borras Cuesta, F., J. Golvano, P. Sarobe, J. J. Lasarte, I. Prieto, A. Szabo, J. L. Guillaume, and J. G. Guillet. 1991. Insights on the amino acid side-chain interactions of a synthetic T-cell determinant. Biologicals 19:187.
22. Lasarte, J. J., P. Sarobe, J. Prieto, and F. Borras-Cuesta. 1995. In vivo cytotoxic T-lymphocyte induction may take place via CD8 T helper lymphocytes. Res. Immunol. 146:35.
23. Lasarte, J. J., P. Sarobe, A. Gullon, J. Prieto, and F. Borras Cuesta. 1992. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell. Immunol. 141:211.
24. Castelruiz, Y., E. Larrea, P. Boya, M. P. Civeira, and J. Prieto. 1999. Interferon α subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology 29:1900.
25. Hayashi, H., H. Matsubara, T. Yokota, I. Kuwabara, M. Kanno, H. Koseki, K. Isono, T. Asano, and M. Taniguchi. 1992. Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection. J. Immunol. 149:1223.
26. O'Donnell, P. V., E. Stockert, Y. Obata, and L. J. Old. 1981. Leukemogenic properties of AKR dualtropic (MCF) viruses: amplification of murine leukemia virus-related antigens on thymocytes and acceleration of leukemia development in AKR mice. Virology 112:548.
27. Hartley, J. W., N. K. Wolford, L. J. Old, and W. P. Rowe. 1977. A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc. Natl. Acad. Sci. USA 74:789.
28. + T cells requires tumor responsiveness to IFN-γ. J. Immunol. 166:2276.
29. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 12:677.
30. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32:3267.
31. + T cell help. J. Immunol. 147:4069.
32. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. USA 88:9448.
33. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549.
34. Lopez-Diaz de Cerio, A. L., N. Casares, J. J. Lasarte, P. Sarobe, L. A. Perez-Mediavilla, M. Ruiz, J. Prieto, and F. Borras-Cuesta. 1999. Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. Int. Immunol. 11:2025.
35. + T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J. Invest. Dermatol. 115:1059.
36. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
37. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
38. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
39. Valente, G., L. Ozmen, F. Novelli, M. Geuna, G. Palestro, G. Forni, and G. Garotta. 1992. Distribution of interferon-γ receptor in human tissues. Eur. J. Immunol. 22:2403.
40. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11:571.
41. Langaas, V., S. Shahzidi, J. I. Johnsen, B. Smedsrod, and B. Sveinbjornsson. 2001. Interferon-γ modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res. 21:3733.
42. Mazzolini, G., I. Narvaiza, L. A. Martinez-Cruz, A. Arina, M. Barajas, J. C. Galofre, C. Qian, J. M. Mato, J. Prieto, and I. Melero. 2003. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFN-γ-induced apoptosis. Gene Ther. 10:1067.
43. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1:447.
44. Basham, T. Y., and T. C. Merigan. 1983. Recombinant interferon-γ increases HLA-DR synthesis and expression. J. Immunol. 130:1492.
45. Houghton, A. N., T. M. Thomson, D. Gross, H. F. Oettgen, and L. J. Old. 1984. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J. Exp. Med. 160:255.
46. Brunda, M. J., and D. Rosenbaum. 1984. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res. 44:597.
47. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
48. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
49. Suri-Payer, E., P. J. Kehn, A. W. Cheever, and E. M. Shevach. 1996. Pathogenesis of post-thymectomy autoimmune gastritis: identification of anti-H/ K adenosine triphosphatase-reactive T cells. J. Immunol. 157:1799.
50. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387.